What Does Tysabri PML Monitoring Involve?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specialized Risk Awareness

If you are taking Tysabri, you likely know that regular monitoring for progressive multifocal leukoencephalopathy (PML) is essential. This page draws on established medical information to outline the typical testing and evaluation timeline, helping you understand what to expect during follow-up care.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA-approved prescribing information includes a boxed warning stating that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding the drug immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML typically includes progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JC virus in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination. FDA adverse-event reports from the FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, and balance disorder among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically isolate PML cases, they reflect the broad spectrum of neurological symptoms that may overlap with PML presentation.

Legal Implications and Statute of Limitations in Massachusetts

For patients in Massachusetts who have developed PML after Tysabri treatment, legal considerations regarding the adequacy of warnings are relevant. The boxed warning explicitly states that Tysabri increases PML risk and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether healthcare providers adequately communicated these risks to patients, particularly regarding the significance of anti-JCV antibody status and the increased risk with longer treatment duration. The prescribing information also notes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which may be relevant in cases where such combinations were used. The statute of limitations for product liability claims in Massachusetts is generally three years from the date of injury or from when the injury reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML typically develops after months to years of treatment, with risk increasing significantly after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The date of diagnosis is often the point at which the injury is discovered, but symptoms may have been present earlier. Patients and their families should document the date of first symptoms, date of PML diagnosis, and all Tysabri infusion dates to establish the timeline. Attorney-related considerations include evaluating whether the prescribing physician followed the TOUCH program requirements, whether anti-JCV antibody testing was performed and discussed, and whether the patient was informed of the PML risk in a manner that allowed informed consent. The boxed warning mandates that Tysabri be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), so any delay in diagnosis or discontinuation may be relevant. In summary, Tysabri carries a known risk of PML that is clearly stated in its prescribing information. Patients who develop PML should seek prompt medical evaluation and legal counsel to assess whether the warnings provided were adequate and whether the statute of limitations in Massachusetts has been met. The timeline from exposure to harm, the presence of risk factors, and the adequacy of communication between healthcare providers and patients are central to any legal analysis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. For PML, this often starts from the date of diagnosis, but earlier symptoms may trigger the clock. It is crucial to consult an attorney promptly to ensure your claim is filed within the allowed timeframe.

What are the known risk factors for developing PML while on Tysabri?

The FDA-approved prescribing information identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when assessing the risk-benefit of Tysabri therapy. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.